REPLHealthcare · BiotechnologyThe 8 Wall Street analysts covering Replimune Group, Inc. hold a median 12-month price target of $24 — +33.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 31 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Replimune Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (97): The shares have been drifting up relative to others.
Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on REPL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +33.4% from it.
Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Oct 2026 | Leerink Partners | Maintains | Outperform | $19 → $31 |
| 26 Aug 2026 | JP Morgan | Maintains | Overweight | $20 → $21 |
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | $17 → $20 |
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | — |
| 7 Aug 2026 | Wedbush | Upgrade | Outperform | — |
| 7 Aug 2026 | Wedbush | Upgrade | Outperform | $12 → $19 |
| 4 Aug 2026 | Leerink Partners | Upgrade | Outperform | — |
| 4 Aug 2026 | Leerink Partners | Upgrade | Outperform | $11 → $17 |
| 31 July 2026 | Cantor Fitzgerald | Upgrade | Overweight | — |
| 31 July 2026 | Cantor Fitzgerald | Upgrade | Overweight | — |
| 31 July 2026 | Wedbush | Maintains | Neutral | $9.00 → $12 |
| 31 July 2026 | Wedbush | Maintains | Neutral | — |
| 30 June 2026 | Wedbush | Maintains | Neutral | $6.00 → $9.00 |
| 30 June 2026 | Wedbush | Maintains | Neutral | — |
| 26 June 2026 | JP Morgan | Upgrade | Overweight | — |
| 1 June 2026 | Wedbush | Maintains | Neutral | — |
| 29 May 2026 | JP Morgan | Upgrade | Neutral | — |
| 13 Apr 2026 | Cantor Fitzgerald | Downgrade | Neutral | — |
| 13 Apr 2026 | HC Wainwright & Co. | Downgrade | Sell | — |
| 13 Apr 2026 | Jefferies | Downgrade | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
REPL appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Replimune Group, Inc. returned +71.8% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 91% of US stocks
Cheaper than 11% of US stocks
Cheaper than 81% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 12% of US stocks
Higher than 9% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Replimune Group, Inc. has a market value of $1.7B and an enterprise value of $1.5B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$297.0M.
Free cash flow in the twelve months to 30 June 2026: −$280.5M.
Trailing P/E: −5.2×; forward P/E: −27.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Replimune Group, Inc. employs 465 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Replimune Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Replimune reported $307.8 million in cash at the end of the second quarter. More than 15 institutions wrote prescriptions within 20 business days.
Why it matters — These figures provide REPL watchers with updates on the company’s cash position and prescription activity.
Replimune held its second-quarter fiscal 2027 earnings conference call on October 28, 2026. The excerpt lists company representatives and participating analysts but provides no discussion of results or business updates.
Why it matters — The excerpt confirms the timing and participants of the call, but does not include information about the company’s performance or outlook.
Replimune reported fiscal second-quarter 2027 financial results and provided a corporate update. It said TUDRIQEV was first delivered to advanced melanoma patients on October 6 and that more than 15 institutions have prescribed it.
Why it matters — The update provides REPL watchers with information about the initial delivery and institutional prescribing of TUDRIQEV.
Replimune announced it will host a conference call on October 28, 2026, at 8:00 a.m. ET to discuss fiscal second-quarter 2027 results and provide a corporate update. The quarter ended September 30, 2026.
Why it matters — REPL watchers can hear the company’s financial results and corporate update on the announced call.
A shareholder lawsuit has been filed against Replimune Group, with a lead plaintiff deadline of October 5, 2026. The suit relates to the FDA's April 2026 rejection of Replimune's RP1 resubmission, in which the agency stated that previously communicated study design concerns were never addressed; Replimune had told investors the resubmission was a complete response and that commercial launch teams were ready, and REPL shares fell to $1.70.
Why it matters — Replimune watchers would care because the FDA rejection of the RP1 resubmission, the significant share decline, and the resulting shareholder lawsuit raise regulatory and legal risks around the company's lead product candidate.
The 8 Wall Street analysts covering Replimune Group, Inc. have a median 12-month price target of $24, with estimates ranging from $14 to $31. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Replimune Group, Inc., 7 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Replimune Group, Inc. 61 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Replimune Group, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +33.4% from the last close, and Ticker Nerd's factor model ranks Replimune Group, Inc. 61 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Replimune Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for REPL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $31 over the next 12 months.
Replimune Group, Inc. returned +71.8% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer.
The most recent item we track (The Motley Fool, 29 Oct 2026): "Replimune: 3 Key Takeaways for Long-Term Investors". Replimune reported $307.8 million in cash at the end of the second quarter. More than 15 institutions wrote prescriptions within 20 business days.
Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its current work centers on engineered viral-based treatments designed to infect and destroy tumor cells while also stimulating an immune response against solid tumors. The company’s product pipeline includes therapies built on its proprietary RPx platform, with candidates aimed at multiple cancer settings. Replimune Group, Inc. serves the oncology market by advancing biologic approaches intended to complement or expand existing cancer treatment options. Headquartered in Woburn, Massachusetts, and founded in 2015, the company operates in the United States and the United Kingdom, with an emphasis on research, development, and commercialization of cancer immunotherapy programs.
CEO Dr. Sushil Patel Ph.D. · 465 employees · United States · https://www.replimune.com
